-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $34

Benzinga·12/09/2025 13:17:56
Listen to the news
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $25 to $34.